Research compound

This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.

5-Amino-1MQ

Small-molecule NNMT inhibitor discussed in preclinical metabolic/obesity contexts; human evidence is not established in the open literature.

research-chemicalmetabolicnnmt

Evidence last reviewed: 04 Apr 2026

Buy this ingredient ← Back

Supplement note

Private note on this supplement

Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.

Evidence

2 records

NNMT inhibition & metabolic regulation (preclinical review)

Preclinical models; no human clinical trials identified • Review (preclinical; target-focused)

PUBMEDLow

A 2024 review summarizes NNMT as a therapeutic target for metabolic syndrome, noting preclinical evidence for NNMT inhibitors including 5-amino-1MQ; no human clinical trials have been published as of 2025.

Dose: —

Citation: Liu et al., Front Pharmacol (2024) — Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome

Diet-induced obesity / metabolic endpoints (preclinical)

Animal/preclinical models (as summarized in target-focused literature) • Preclinical summary (target-focused article)

PUBMEDLow

Literature discussing NNMT inhibition reports preclinical benefits on obesity-related outcomes; statements about 5-amino-1MQ efficacy are not equivalent to replicated human trials.

Dose: —

Citation: An et al., Experimental Neurology (2025) — NNMT as target; includes 5-amino-1MQ activity notes

Forms

Small molecule (research)

Evidence primarily preclinical; translation uncertain.

Stacks containing 5-Amino-1MQ

Public community stacks that include this ingredient.

Explore all stacks →

No public stacks include this ingredient yet.